Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme

BACKGROUND & AIMS: Optimally effective treatment for hepatitis C virus genotype 3 (GT3) is urgently needed, particularly in advanced liver disease. Daclatasvir plus sofosbuvir was efficacious in phase 3 studies. Real‐world data for daclatasvir+sofosbuvir in advanced GT3 infection are presented f...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Liver Int
Auteurs principaux: Hézode, Christophe, Lebray, Pascal, De Ledinghen, Victor, Zoulim, Fabien, Di Martino, Vincent, Boyer, Nathalie, Larrey, Dominique, Botta‐Fridlund, Danielle, Silvain, Christine, Fontaine, Hélène, D'Alteroche, Louis, Leroy, Vincent, Bourliere, Marc, Hubert‐Fouchard, Isabelle, Guyader, Dominique, Rosa, Isabelle, Nguyen‐Khac, Eric, Fedchuk, Larysa, Akremi, Raoudha, Bennai, Yacia, Filipovics, Anne, Zhao, Yue, Bronowicki, Jean‐Pierre
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2017
Sujets:
Viral Hepatitis
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5600115/
https://ncbi.nlm.nih.gov/pubmed/28177199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/liv.13383
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires